Effect of a Specialized Oral Supplement on Nutritional Status and Quality of Life in Non-dialysis CKD

Prior treatment

• Previous hospitalizations in the last month
• Initiation of replacement therapy.

Other illness

• Patients with serious complications (chronic infection, septicemia, cancer, HIV, Alzheimer's, uncontrolled heart failure, liver failure, cerebrovascular syndrome, malabsorption syndrome, or allergy to any ingredient in the nutritional supplement)
• Failure to attend nutritional assessment and biochemical testing at baseline, 2 months, and end of the study.
• Failure to take the supplement \>10% (\>12 failed doses).

Other

• Patients with actual consumption of food supplements and / or keto analogues.
  • Elimination Criteria:
• Diagnosis of any comorbidity during the intervention period.
• Identification of adverse effects.
• Withdrawal of voluntary participation by the patient.
• Death.

• Patients over 18 years of age
• Patients with diabetic kidney with eGFR \<60 ml / min / 1.73m2 and ≥15 ml / min / 1.73m2, (stage G3a, G3b and G4 respectively)
• Patients with protein energy expenditure (defined by serum albumin \< 3.8 g/dl)
• Patients with protein energy expenditure (defined by 24-hour recall less than a dietary protein intake \<0.6 g/kg/d or have a consumption \<25 kcal/kg/d
• Patients who can read and write (or primary caregiver)
• Domicile within the metropolitan area